Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- DOI
- 10.1136/bmjopen-2025-112318
- Published
- 2025 Dec 24
- Container
- BMJ open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2025-112318,
title = {Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.},
author = {Kimura Y and Koda T and Kurakami H and Sakamoto S and Iwasaki K and Asai K and Ge L and Kato H and Tsuboi T and Matsukawa N and Kano O and Matsuse D and Tomiyama M and Yokoe M and Nagai Y and Mochizuki H},
year = {2025},
journal = {BMJ open},
doi = {10.1136/bmjopen-2025-112318},
url = {https://doi.org/10.1136/bmjopen-2025-112318}
}RIS
TY - JOUR TI - Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study. AU - Kimura Y AU - Koda T AU - Kurakami H AU - Sakamoto S AU - Iwasaki K AU - Asai K AU - Ge L AU - Kato H AU - Tsuboi T AU - Matsukawa N AU - Kano O AU - Matsuse D AU - Tomiyama M AU - Yokoe M AU - Nagai Y AU - Mochizuki H PY - 2025 JO - BMJ open DO - 10.1136/bmjopen-2025-112318 UR - https://doi.org/10.1136/bmjopen-2025-112318 ER -
APA
Y, K., T, K., H, K., S, S., K, I., K, A., L, G., H, K., T, T., N, M., O, K., D, M., M, T., M, Y., Y, N., & H, M. (2025). Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.. BMJ open. https://doi.org/10.1136/bmjopen-2025-112318
Source records
- pubmed · retrieved 2026-09-26T20:22:01.710Z